MicroRNA‐431‐5p inhibits angiogenesis, lymphangiogenesis, and lymph node metastasis by affecting TGF‐β1/SMAD2/3 signaling via ZEB1 in gastric cancer
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23731 ↗At a glance
Journal article in Molecular Carcinogenesis, 2024. Written by Pengpeng Liu and 9 co-authors. Institution: The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Major MEDLINE topics: Stomach Neoplasms, MicroRNAs, Lymphatic Metastasis, Lymphangiogenesis. Cited 10 times so far (Crossref); 41 references. Funded by: Hebei Provincial Government-funded Clinical Talent Project, Hebei Provincial Major Science and Technology Special Project, Beijing-Tianjin-Hebei Basic Research Cooperation Special Project.
Abstract (original language)
Accumulating evidence suggests that lymphangiogenesis plays a crucial role in lymphatic metastasis, leading to tumor immune tolerance. However, the specific mechanism remains unclear. In this study, miR‐431‐5p was markedly downregulated in both gastric cancer (GC) tissues and plasma exosomes, and its expression were correlated negatively with LN metastasis and poor prognosis. Mechanistically, miR‐431‐5p weakens the TGF‐β1/SMAD2/3 signaling pathway by targeting ZEB1, thereby suppressing the secretion of VEGF‐A and ANG2, which in turn hinders angiogenesis, lymphangiogenesis, and lymph node (LN) metastasis in GC. Experiments using a popliteal LN metastasis model in BALB/c nude mice demonstrated that miR‐431‐5p significantly reduced popliteal LN metastasis. Additionally, miR‐431‐5p enhances the efficacy of anti‐PD1 treatment, particularly when combined with galunisertib, anti‐PD1 treatment showing a synergistic effect in inhibiting GC progression in C57BL/6 mice. Collectively, these findings suggest that miR‐431‐5p may modulate the TGF‐β1/SMAD2/3 pathways by targeting ZEB1 to impede GC progression, angiogenesis, and lymphangiogenesis, making it a promising therapeutic target for GC management.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer, Shijiazhuang, Hebei, China.
- Big data analysis and mining application for precise diagnosis and treatment of gastric cancer Hebei Provincial Engineering Research Center, Shijiazhuang, Hebei, China.
- Research Center and Tumor Research Institute of the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
ORCID profiles: Pengpeng Liu
Funding
- Hebei Provincial Government-funded Clinical Talent Project
- Hebei Provincial Major Science and Technology Special Project
- Beijing-Tianjin-Hebei Basic Research Cooperation Special Project
Cite
APA
Liu, P., Ding, P., Yang, J., Wu, H., Wu, J., Guo, H., Yang, P., Tian, Y., Meng, L., & Zhao, Q. (2024). MicroRNA‐431‐5p inhibits angiogenesis, lymphangiogenesis, and lymph node metastasis by affecting TGF‐β1/SMAD2/3 signaling via ZEB1 in gastric cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23731
Vancouver
Liu P, Ding P, Yang J, Wu H, Wu J, Guo H, et al. MicroRNA‐431‐5p inhibits angiogenesis, lymphangiogenesis, and lymph node metastasis by affecting TGF‐β1/SMAD2/3 signaling via ZEB1 in gastric cancer. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23731
BibTeX
@article{Liu2024,
author = {Liu, Pengpeng and Ding, Ping'an and Yang, Jiaxuan and Wu, Haotian and Wu, Jiaxiang and Guo, Honghai and Yang, Peigang and Tian, Yuan and Meng, Lingjiao and Zhao, Qun},
title = {MicroRNA‐431‐5p inhibits angiogenesis, lymphangiogenesis, and lymph node metastasis by affecting TGF‐β1/SMAD2/3 signaling via ZEB1 in gastric cancer},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23731}
}
EUVIMED